P lantar fasciitis is a common cause of heel pain. The diagnosis is primarily based on history and clinical findings, and further investigations are rarely required. Prolonged weight bearing, obesity, and reduced plantar flexion are well-described risk factors.
In 10% of cases, patients do not improve with conservative measures and the disease becomes chronic. 3 Delay in starting treatment, obesity, and bilateral disease are risk factors for chronic disease. 4 Local injection of platelet-rich plasma is an emerging concept in treating recalcitrant tendon and ligament pathologies, including plantar fasciitis. Platelet-rich plasma injection delivers platelets and growth factors in high concentrations directly to the site of injury, which otherwise is inaccessible to growth factors as a result of hypovasPlantar fasciitis is a common cause of heel pain. It is a disabling disease in its chronic form. It is a degenerative tissue condition of the plantar fascia rather than an inflammation. Various treatment options are available, including nonsteroidal anti-inflammatory drugs, corticosteroid injections, orthosis, and physiotherapy. This study compared the effects of local platelet-rich plasma, corticosteroid, and placebo injections in the treatment of chronic plantar fasciitis. In this double-blind study, patients were divided randomly into 3 groups. Local injections of platelet-rich plasma, corticosteroid, or normal saline were given. Patients were assessed with the visual analog scale for pain and with the American Orthopaedic Foot and Ankle Society (AOFAS) Ankle and Hindfoot score before injection, at 3 weeks, and at 3-month follow-up. Mean visual analog scale score in the platelet-rich plasma and corticosteroid groups decreased from 7.44 and 7.72 preinjection to 2.52 and 3.64 at final follow-up, respectively. Mean AOFAS score in the platelet-rich plasma and corticosteroid groups improved from 51.56 and 55.72 preinjection to 88.24 and 81.32 at final follow-up, respectively. There was a significant improvement in visual analog scale score and AOFAS score in the platelet-rich plasma and corticosteroid groups at 3 weeks and at 3-month follow-up. There was no significant improvement in visual analog scale score or AOFAS score in the placebo group at any stage of the study. The authors concluded that local injection of platelet-rich plasma or corticosteroid is an effective treatment option for chronic plantar fasciitis. Platelet-rich plasma injection is as effective as or more effective than corticosteroid injection in treating chronic plantar fasciitis. [Orthopedics. 2016; 39(2):e285-e289.] cularity and hypocellularity. 5 To the best of the authors' knowledge, no study has evaluated the effect of platelet-rich plasma in chronic plantar fasciitis with a placebo control group. Although previous studies compared platelet-rich plasma and corticosteroid injection with variable results, comparison with a placebo control group is important in showing that the improvement is the result of treatment only and not the routine course of disease. This study is the first prospective randomized double-blind placebo control study to compare the effectiveness of platelet-rich plasma and corticosteroid in chronic plantar fasciitis.
Materials and Methods
Institutional review board approval was obtained, and all patients provided informed consent. The study included 75 patients with chronic plantar fasciitis. Patients were diagnosed on the basis of history and physical examination, including heel pain and tenderness over the plantarmedial aspect of the calcaneal tuberosity, near the insertion of the plantar fascia. In patients with bilateral planter fasciitis, only the right heel was included in the study. Patients had not responded to at least 3 months of conservative therapy, including physical therapy, NSAIDs, bracing, and orthotics. Treatment with NSAIDs was discontinued 1 week before injection. Participants were randomly divided by computer-derived random charts into 3 groups. Group A was assigned to receive platelet-rich plasma, group B was assigned to receive corticosteroid, and group C was assigned to receive normal saline.
For preparation of platelet-rich plasma in group A, 27 mL of blood was withdrawn from the cubital vein and placed in a glass tube containing 3 mL of citrate dextrose solution. Citrate dextrose solution was used to prevent clotting. The blood was centrifuged at 3200 rpm for 12 minutes, and 2.5 to 3 mL of platelet-rich plasma was obtained by this method. No activating agents were used. Only 5 mL of blood was extracted from patients in groups B and C. Patients did not know the amount of blood extracted. In group B, 2 mL of 40 mg of methylprednisolone was used for injection.
The injection was given at the point of maximum tenderness in the heel with a 22-g needle using a peppering technique. This technique involved use of a single skin portal and 4 to 5 penetrations of the fascia. During injection, a screen was placed between the patient's face and the injection area so that the patient could not see the syringe or the content of the injection. Injections were given under aseptic conditions as a day procedure. Patients were instructed not to use NSAIDs for 1 month after the procedure. After the injection, patients were advised to apply ice for pain relief if required and to continue to wear comfortable shoes with cushions. All patients had physical therapy to stretch the calf muscle and plantar fascia.
Patients were assessed before injection and during follow-up at 3 weeks and 3 months by a blinded observer working in the authors' department as a resident physician. Assessment was conducted with the visual analog scale for pain and the American Orthopaedic Foot and Ankle Society (AOFAS) Ankle and Hindfoot score.
In groups A, B, and C, preinjection visual analog scale and AOFAS scores were compared with visual analog scale and AOFAS scores at 3 weeks of follow-up with paired 2-tailed Student's t test. Similarly, preinjection visual analog scale and AOFAS scores were compared with visual analog scale and AOFAS scores at 3 months of follow-up using paired 2 Mean visual analog scale and AOFAS scores improved over time after injection in groups A and B. In group A, visual analog scale score decreased significantly from preinjection level at follow-up of 3 weeks (P=0) and 3 months (P=0). Compared with the preinjection level, AOFAS score improved significantly at follow-up of 3 weeks (P=0) and 3 months (P=0). Similarly, in group B, visual analog scale score decreased significantly from preinjection level at follow-up of 3 weeks (P=0) and 3 months (P=0). The AOFAS score improved significantly at follow-up of 3 weeks (P=0) and 3 months (P=0) in group B. In group C, no significant difference was seen between preinjection visual analog scale score and visual analog scale score at 3 weeks (P=.11) or between preinjection visual analog scale score and visual 
discussion
Many authors consider plantar fasciitis a degenerative tissue condition rather than inflammation at the site of origin of the plantar fascia at the medial tuberosity of the calcaneous. 6, 7 Degeneration of collagen occurs at the site of the lesion because of microtears of the fascia that do not heal. The histologic features of chronic plantar fasciitis show no inflammatory cell invasion at the site of the lesion, and the normal fascia and surrounding tissue are replaced by angiofibroblastic hyperplastic tissue. 7, 8 Platelet-rich plasma injection delivers platelets with growth factors in high concentrations directly to the site of the lesion, which otherwise is inaccessible to growth factors because of hypovascularity and hypocellularity. 9 The cytokines in platelet alpha granules affect the healing stages necessary to reverse chronic plantar fasciitis by enhancing fibroblast migration and proliferation, increase vascularization, and improve collagen deposition. 10 Previous studies described plateletrich plasma injection as an effective treatment option for chronic plantar fasciitis ( Table 4) . [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Monto 11 found that platelet-rich plasma injection was more effective and durable than corticosteroid injection at 2 years of follow-up in a study of 40 patients.
Shetty et al 12 compared the effectiveness of platelet-rich plasma and corticosteroid injections in 60 patients and found no significant difference at 6 months of follow-up. Peerbooms et al 13 performed a randomized controlled multicenter trial of 120 patients comparing platelet-rich plasma and corticosteroid injections, but the results were not published. When Aksahin et al 14 compared intralesional corticosteroid and platelet-rich plasma injections for plantar fasciitis, the treatments were found to be equally effective. In a prospective randomized study, Lee and Ahmad 15 compared intralesional autologous blood injection with corticosteroid injection in patients with chronic plantar fasciitis. At 6 weeks and 3 months of follow-up, the corticosteroid group had significantly lower visual analog scale scores than the autologous blood group, but the difference was not significant at 6 months. The corticosteroid group had a significantly higher tenderness threshold than the autologous blood group at 6 weeks, 3 months, and 6 months of follow-up. 15 The current study found that local platelet-rich plasma and corticosteroid injections were effective at 3 weeks and 3 months of follow-up, with significant improvement in visual analog scale and AOFAS scores. This was not the case with placebo injection. Comparison of platelet-rich plasma and corticosteroid injections showed no significant difference at 3 weeks of follow-up. At 3 months of follow-up, platelet-rich plasma injection had significantly better outcomes compared with corticosteroid injection, based on AOFAS score, but both procedures had the same outcomes, based on visual analog scale score.
Platelet-rich plasma was administered at the point of maximum tenderness of the heel. Some studies advocate an ultrasound-guided technique for administering injection in plantar fasciitis. 21, 22 However, Kane et al 23 reported no significant difference in their comparative study between ultrasound-guided and palpation-guided injection techniques in the management of idiopathic plantar fasciitis. In previous studies, platelet-rich plasma injection was administered with a peppering technique where the fascia was injected at multiple sites through a single skin portal. 13, [17] [18] [19] Other authors used a medial approach to administer platelet-rich plasma. 14, 16 It is not known whether either technique is superior. In the current study, the peppering technique was used.
Platelet concentration in platelet-rich plasma varies depending on the method of preparation. Preparations with a high concentration of platelets have a greater level of restorative growth factors. There is no final consensus regarding the threshold concentration of platelets in plateletrich plasma. In addition, the superiority of leukocyte-reduced or leukocyte-rich platelet-rich plasma is debatable. 24, 25 In the current study, leukocytes were not separated from platelet-rich plasma.
Limitations
The sample size in the current study was small, and further study with a larger sample is required to confirm the results.
conclusion
Local injection of platelet-rich plasma or corticosteroid is an effective treatment option for chronic plantar fasciitis. The authors believe that platelet-rich plasma injection is as effective as or more effective than corticosteroid injection at 3 months of follow-up.
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